A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
Latest Information Update: 12 Dec 2024
At a glance
- Drugs Ezaladcigene resoparvovec (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Acronyms RESTORE-1
- Sponsors Neurocrine Biosciences; Voyager Therapeutics
Most Recent Events
- 10 Dec 2024 Status changed from active, no longer recruiting to completed.
- 08 Dec 2023 Phase of this clinical trial has been changed from 2 to 1. Primary endpoint changed so that the trial focus is also changed from TU to AR.
- 08 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Nov 2024.